TP53 and head and neck squamous cell carcinoma: Adenoviral therapeutic strategies, such as Ad-p53 and ONYX-015, and small molecular compounds, have progressed to clinical trials in the HNSCC but have shown a very mild activity 113, 122, 126, 127.